{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=tocilizumab&page=2", "query": { "intervention": "tocilizumab", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=tocilizumab&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-09-27T00:02:25.859Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04372186", "title": "A Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Participants With COVID-19 Pneumonia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "COVID-19 Pneumonia" ], "interventions": [ { "name": "Placebo", "type": "DRUG" }, { "name": "Tocilizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Genentech, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 377, "start_date": "2020-05-14", "completion_date": "2020-09-22", "has_results": true, "last_update_posted_date": "2023-02-10", "last_synced_at": "2026-09-27T00:02:25.859Z", "location_count": 32, "location_summary": "Phoenix, Arizona • Tucson, Arizona • El Centro, California + 28 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "El Centro", "state": "California" }, { "city": "La Mesa", "state": "California" }, { "city": "Oakland", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04372186" }, { "nct_id": "NCT03275103", "title": "Dose-Escalation Study of Cevostamab in Participants With Relapsed or Refractory Multiple Myeloma (R/R MM)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "Cevostamab", "type": "DRUG" }, { "name": "Tocilizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Genentech, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 355, "start_date": "2017-09-19", "completion_date": "2026-01-07", "has_results": false, "last_update_posted_date": "2026-02-05", "last_synced_at": "2026-09-27T00:02:25.859Z", "location_count": 10, "location_summary": "Birmingham, Alabama • Scottsdale, Arizona • Duarte, California + 6 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT03275103" }, { "nct_id": "NCT00365001", "title": "A Drug Interaction Study Between Tocilizumab, Methotrexate and Simvastatin on Patients With Rheumatoid Arthritis.", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Rheumatoid Arthritis" ], "interventions": [ { "name": "tocilizumab [RoActemra/Actemra]", "type": "DRUG" }, { "name": "Methotrexate", "type": "DRUG" }, { "name": "Simvastatin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 23, "start_date": null, "completion_date": "2008-04", "has_results": false, "last_update_posted_date": "2010-06-11", "last_synced_at": "2026-09-27T00:02:25.859Z", "location_count": 10, "location_summary": "Anniston, Alabama • Scottsdale, Arizona • Little Rock, Arkansas + 7 more", "locations": [ { "city": "Anniston", "state": "Alabama" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Palm Harbor", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT00365001" }, { "nct_id": "NCT01696929", "title": "An Open-Label Trial of Tocilizumab in Schizophrenia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Schizophrenia" ], "interventions": [ { "name": "Tocilizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Brian Miller", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "50 Years", "sex": "ALL", "summary": "18 Years to 50 Years" }, "enrollment_count": 8, "start_date": "2012-09", "completion_date": "2014-12", "has_results": true, "last_update_posted_date": "2021-07-29", "last_synced_at": "2026-09-27T00:02:25.859Z", "location_count": 1, "location_summary": "Augusta, Georgia", "locations": [ { "city": "Augusta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT01696929" }, { "nct_id": "NCT02682823", "title": "Tocilizumab Real-Life Human Factors (RLHFs) Validation Study", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Rheumatoid Arthritis" ], "interventions": [ { "name": "AI-1000 G2", "type": "DEVICE" }, { "name": "Tocilizumab", "type": "DRUG" } ], "intervention_types": [ "DEVICE", "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 91, "start_date": "2016-03-21", "completion_date": "2016-07-29", "has_results": true, "last_update_posted_date": "2019-04-19", "last_synced_at": "2026-09-27T00:02:25.859Z", "location_count": 8, "location_summary": "Mesa, Arizona • Los Alamitos, California • Santa Maria, California + 5 more", "locations": [ { "city": "Mesa", "state": "Arizona" }, { "city": "Los Alamitos", "state": "California" }, { "city": "Santa Maria", "state": "California" }, { "city": "Lexington", "state": "Kentucky" }, { "city": "Tulsa", "state": "Oklahoma" } ], "official_url": "https://clinicaltrials.gov/study/NCT02682823" }, { "nct_id": "NCT02165345", "title": "Extension Study Evaluating the Safety and Efficacy of Subcutaneous Tocilizumab (RoActemra/Actemra) Administration in Systemic and Polyarticular-Course Juvenile Idiopathic Arthritis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Juvenile Idiopathic Arthritis" ], "interventions": [ { "name": "Tocilizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Years", "maximum_age": "18 Years", "sex": "ALL", "summary": "2 Years to 18 Years" }, "enrollment_count": 82, "start_date": "2014-07-16", "completion_date": "2021-11-24", "has_results": false, "last_update_posted_date": "2022-02-23", "last_synced_at": "2026-09-27T00:02:25.859Z", "location_count": 9, "location_summary": "Little Rock, Arkansas • Chicago, Illinois • Hackensack, New Jersey + 6 more", "locations": [ { "city": "Little Rock", "state": "Arkansas" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Hackensack", "state": "New Jersey" }, { "city": "Durham", "state": "North Carolina" }, { "city": "Cincinnati", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT02165345" }, { "nct_id": "NCT04356937", "title": "Efficacy of Tocilizumab on Patients With COVID-19", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "SARS-CoV 2" ], "interventions": [ { "name": "Tocilizumab", "type": "DRUG" }, { "name": "Placebos", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Massachusetts General Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "85 Years", "sex": "ALL", "summary": "18 Years to 85 Years" }, "enrollment_count": 243, "start_date": "2020-04-20", "completion_date": "2020-08-27", "has_results": true, "last_update_posted_date": "2021-07-27", "last_synced_at": "2026-09-27T00:02:25.859Z", "location_count": 3, "location_summary": "Boston, Massachusetts • Newton, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Newton", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT04356937" }, { "nct_id": "NCT00535782", "title": "A Study of the Effect of Tocilizumab on Markers of Atherogenic Risk in Patients With Moderate to Severe Rheumatoid Arthritis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Rheumatoid Arthritis" ], "interventions": [ { "name": "Tocilizumab", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Methotrexate", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 132, "start_date": "2007-10-31", "completion_date": "2011-01-31", "has_results": true, "last_update_posted_date": "2017-07-26", "last_synced_at": "2026-09-27T00:02:25.859Z", "location_count": 26, "location_summary": "Anniston, Alabama • Huntsville, Alabama • Scottsdale, Arizona + 22 more", "locations": [ { "city": "Anniston", "state": "Alabama" }, { "city": "Huntsville", "state": "Alabama" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00535782" }, { "nct_id": "NCT03869190", "title": "Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatments and Combinations in Patients With Urothelial Carcinoma (MORPHEUS-UC)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Urothelial Carcinoma", "Bladder Cancer" ], "interventions": [ { "name": "Atezolizumab", "type": "DRUG" }, { "name": "Enfortumab Vedotin", "type": "DRUG" }, { "name": "Niraparib", "type": "DRUG" }, { "name": "Magrolimab (Hu5F9-G4)", "type": "DRUG" }, { "name": "Tiragolumab", "type": "DRUG" }, { "name": "Sacituzumab Govitecan", "type": "DRUG" }, { "name": "Tocilizumab", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 272, "start_date": "2019-06-01", "completion_date": "2025-12-22", "has_results": true, "last_update_posted_date": "2026-08-03", "last_synced_at": "2026-09-27T00:02:25.859Z", "location_count": 10, "location_summary": "Los Angeles, California • San Francisco, California • Stanford, California + 6 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "Lexington", "state": "Kentucky" }, { "city": "Louisville", "state": "Kentucky" } ], "official_url": "https://clinicaltrials.gov/study/NCT03869190" }, { "nct_id": "NCT03708224", "title": "Preoperative Immunotherapy in Patients With Squamous Cell Carcinoma of the Head and Neck", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Cancer", "Carcinoma", "Squamous Cell Carcinoma", "Head and Neck Cancer" ], "interventions": [ { "name": "Atezolizumab", "type": "BIOLOGICAL" }, { "name": "Tocilizumab", "type": "BIOLOGICAL" }, { "name": "Tiragolumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Alain Algazi", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 55, "start_date": "2019-03-08", "completion_date": "2027-07-31", "has_results": false, "last_update_posted_date": "2026-08-11", "last_synced_at": "2026-09-27T00:02:25.859Z", "location_count": 1, "location_summary": "San Francisco, California", "locations": [ { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03708224" } ] }